Vitiligo with shorter DS: adding NDCS to NCES boosts repigmentation rate

  • Thakur V & al.
  • JAMA Dermatol
  • 2 Jan 2019

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Results from a small randomized clinical trial suggest that transplanting a combination of noncultured dermal and epidermal cell suspensions (NDCS+NCES) is associated with higher repigmentation rates vs NCES alone in patients with short duration of clinical stability (DS; 3-6 months).

Why this matters

  • Pilot study suggests that dermal mesenchymal stem cells from NDCS might improve efficacy of NCES.

Key results

  • In patients with DS of 3-6 months, NDCS+NCES was associated with a higher rate of >75% repigmentation at 24 weeks compared with NCES alone (100% vs 30%; P=.003).
  • In patients with DS >12 months, NDCS+NCES and NCES alone were associated with similar rates of >75% repigmentation at 24 weeks (60% vs 70%; P>.99).

Study design

  • 40 patients with focal, segmental, or generalized vitiligo were included.
  • 20 patients had DS of 3-6 months; 20 patients had DS >12 months.
  • Within each clinical stability subgroup, 10 patients received NDCS+NCES and 10 patients received NCES alone.
  • Funding: None disclosed.

Limitations

  • Small sample size.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit